Compare Abbott Laboratories (ABT) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Goodyear Tire & Rubber Co — how do they compare? Abbott Laboratories trades at $109.09 (market cap $187.95B), while Goodyear Tire & Rubber Co trades at $6.12 (market cap $1.75B). The key difference: Abbott Laboratories is far larger — about 107.4× Goodyear Tire & Rubber Co's market cap, and Abbott Laboratories pays a 2.32% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.
| ABT | GT | |
|---|---|---|
Market Cap | $187.95B | $1.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $10.54 |
52-Week Low | $82.57 | $5.58 |
Enterprise Value | $214.96B | $9.11B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Goodyear Tire & Rubber (GT) trades at $6.03, down 6.37% over 24 hours, reflecting bearish technical signals and weak fundamentals. The stock shows negative profitability with a net income margin of -14.37% and ROE of -63.93% as of 2025, while recent Q2 2026 earnings missed on EPS but beat revenue estimates. Cash flow improved to a net $46 million in 2025, yet debt levels remain elevated with a debt-to-asset ratio of 34.36%.
Outlook remains challenging due to volume pressures and high costs, though analyst consensus leans hold (50%) with some buy support (34.62%). Key risks include sustained losses, competitive pressures, and macroeconomic headwinds impacting tire demand, requiring careful monitoring of turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
